Corrigendum: ADAM10-mediated ephrin-B2 shedding promotes myofibroblast activation and organ fibrosis.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

3 citing papers in PubMed, 16 citations in OpenAlex.

1. Nociceptive sensory neuron-derived NGF orchestrates a fibrotic mesenchymal stromal cell neurogenic niche to drive tendon pathological fibrosis.Nature communications · 2025
   Article
2. Novel insights into systemic sclerosis using a sensitive computational method to analyze whole-genome bisulfite sequencing data.Clinical epigenetics · 2023
   Article
3. Targeting cardiomyocyte ADAM10 ectodomain shedding promotes survival early after myocardial infarction.Nature communications · 2022
   Article

Corrections and comments

• Erratum for
  ADAM10-mediated ephrin-B2 shedding promotes myofibroblast activation and organ fibrosis.2017

Authors and funding

25 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract